Evidence map›Paper›PMID 29387205›Full record

ArticleExperimental and therapeutic medicine2018

miR-144 inhibits growth and metastasis of cervical cancer cells by targeting VEGFA and VEGFC.

Pingping Tao, Hao Wen, Binlie Yang, Ai Zhang, Xiaohua Wu, Qing Li

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and therapeutic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 34 citations in OpenAlex.

  1. MicroRNAs as Biomarkers of Cervical Cancers.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. [Over-expression of miR-144 inhibits invasion of liver cancer SMMC-7721 cellsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Pingping TaoDepartment of Obstetrics and Gynecology, People's Hospital of Shanghai Pudong New Area, Shanghai 201299, P.R. China.
Hao WenDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China.
Binlie YangDepartment of Obstetrics and Gynecology, People's Hospital of Shanghai Pudong New Area, Shanghai 201299, P.R. China.
Ai ZhangDepartment of Obstetrics and Gynecology, People's Hospital of Shanghai Pudong New Area, Shanghai 201299, P.R. China.
Xiaohua WuDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China.
Qing LiDepartment of Pathology, People's Hospital of Shanghai Pudong New Area, Shanghai 201299, P.R. China.
Pudong New Area People's Hospital · CNFudan University Shanghai Cancer Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRs) are aberrantly expressed in various cancer types and have critical roles in their genesis and progression. miR-144 has been identified to be involved in the development of hepatocellular carcinoma and rectal cancer. However, the roles of miR-144 in cervical cancer and the underlying molecular mechanisms have remained elusive. The present study identified that miR-144 was significantly decreased in cervical cancer tissues compared with that in matched normal cervical tissues as well as in metastatic vs. non-metastatic cervical cancer tissues. miR-144 downregulation was significantly associated with the International Federation of Gynecology and Obstetrics stage and lymph node metastasis. In a gain-of function study, miR-144 mimics were transfected into the Hela and C33A cervical cancer cell lines, which led to suppression of cell growth. In addition, overexpression of miR-144 inhibited the migration and invasion of Hela and C33A cells. Furthermore, a bioinformatics analysis identified vascular endothelial growth factor A (VEGFA) VEGFC as two novel target genes of miR-144. Of note, a dual luciferase reporter assay, reverse-transcription quantitative polymerase chain reaction analysis and western blot analysis demonstrated that miR-144 repressed the expression of VEGFA and VEGFC by directly targeting to their 3'-untranslated region. Taken together, the results suggested that miR-144 acts as a tumor suppressor in the proliferation and metastasis of cervical cancer cells by directly targeting VEGFA and VEGFC, suggesting that miR-144 may be a novel promising diagnostic and therapeutic biomarker for cervical cancer.

Indexed as

cervical cancermicroRNA-144microRNAssuppressorvascular endothelial growth factor Avascular endothelial growth factor C

Identifiers

PMID29387205
PMCPMC5769280
OpenAlexW2765088952

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.